Study of BHV-4157 in Alzheimer's Disease

Biohaven Pharmaceuticals, Inc.350 enrolled

Overview

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, were administered orally once daily. Duration of treatment is 48 weeks in double-blind phase. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period. Eligible participants who completed the double-blind treatment phase had the opportunity to receive open-label troriluzole for up to 48 weeks in an open-label extension (OLE) phase.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

350

Conditions

Alzheimer Disease

Interventions

troriluzoleDRUG

Oral BHV-4157 will be given daily for up to 48 weeks

Placebo oral capsuleDRUG

Oral matching placebo will be given daily for up to 48 weeks

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Age 50 to 85 (inclusive) at screening * Diagnosed with probable Alzheimer's disease dementia: Core clinical criteria in accordance with NIA/Alzheimer's Association Guidelines. * Living in the community (includes assisted living facilities, but excludes long-term care nursing facilities). * Ambulatory, or able to walk with an assistive device, such as a cane or walker. * Participants must have a study partner who has frequent interaction with them (approximately \>3-4 times per week), will be present for all clinic visits, and can assist in compliance with study procedures. * An Mini-Mental State Examination score of 14 to 24, inclusive, at screening. * A brain MRI scan within 6 months of screening consistent with a diagnosis of Alzheimer's disease. * Participants should be treated with a stable dosage regimen of FDA-approved AD medications (acetylcholinesterase inhibitors (AchEI) and/or memantine) for at least 3 months prior to screening. Participants should be expected to remain on a stable dosage regimen of these medications for the duration of the trial. * Participants who are not being treated with FDA-approved AD medications at the time of screening, because they have contraindications to these medications, or because they have previously failed treatment with these medications, are also eligible for inclusion, if it is expected that they will not be treated with these medications for the duration of the trial. Key Exclusion Criteria: * Hepatic impairment defined as Child-Pugh class of A or more severe liver impairment. * Other neurodegenerative diseases and causes of dementias, including Parkinson's disease and Huntington's disease, vascular dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP (Progressive Supranuclear Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure hydrocephalus). * History of a major depressive episode within the past 6 months of screening. * Insulin-dependent diabetes or uncontrolled diabetes with HbA1c value \>8.0 %. * Cancer or a malignant tumor within the past 3 years, except patients who underwent potentially curative therapy with no evidence of recurrence for \>3 years. Patients with stable prostate cancer or non-melanoma skin cancers are not excluded. * Participation in another clinical trial for an investigational agent and having taken at least one dose of study medication, unless confirmed as having been on placebo, within 12 weeks prior to screening. The end of a previous investigational trial is defined as the date of the last dose of an investigational agent.

Locations (44)

Outcomes

Primary Outcomes

Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 48

The ADAS-Cog is a structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing a letter in an envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions were also obtained. The test was scored in terms of errors on a scale ranging from 0 (best) to 70 (worse), with higher scores indicate poorer performance and greater impairment.

Time frame: Baseline (Day 1) and Week 48

Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-Sum of Boxes) Total Score at Week 48

The CDR-sum of boxes is a validated composite rating of cognition and everyday functioning used in longitudinal AD research which incorporates both informant input and direct assessment of performance. It assesses through semi-structured interview 3 cognitive domains including memory, orientation, and judgement/problem solving and 3 everyday functional domains including community affairs, home and hobbies and personal care. The individual domain score ranging from 0 (none) to 3 (severe) but the scores in each of these were combined to obtain a composite score (sum of boxes) ranging from 0 (best) to 18 (worst), with higher scores indicate poorer performance and greater impairment. The individual domain scores are added to create a sum of the box scores.

Time frame: Baseline (Day 1) and Week 48

Secondary Outcomes

Change From Baseline in Magnetic Resonance Imaging (MRI) Hippocampal Volume at Week 48

Volumetric MRI allows the in vivo assessment of brain structure volume and provides a measure of atrophy rate. Results from MRI studies suggest that the patterns of atrophy in AD, which mirror the pathological progression of the disease, can reliably be detected and tracked across time. Hippocampal volume derived from MRI correlates with histological hippocampal volume and degree of neuronal loss and AD pathology, and entorhinal cortical thickness change appears to be an early and sensitive indicator of neurodegeneration associated with AD.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Xenoscience, Inc.

Phoenix, Arizona, United States

Barrow Neurological Institute

Phoenix, Arizona, United States

Banner Sun Health Research Institute

Sun City, Arizona, United States

Neurology Center of North Orange County

Fullerton, California, United States

University of California, San Diego

La Jolla, California, United States

University of Southern California

Los Angeles, California, United States

SC3 Research Group - Pasadena

Pasadena, California, United States

Geriatric and Adult Psychiatry

Hamden, Connecticut, United States

Yale University School of Medicine

New Haven, Connecticut, United States

Ki Health PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH

Stamford, Connecticut, United States

...and 34 more locations